Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of L-105 (rifaximin) in hepatic encephalopathy
jRCT2080222041Phase 3
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rifaximin in hepatic encephalopathy (HE), sponsored by ASKA Pharmaceutical Holdings Co., Ltd.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on jRCT2080222041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222041.